Please login to the form below
sitagliptin
This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.
Givlaari, Rybelsus lead crowded CHMP recommendations
In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved greater blood glucose reductions compared to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), Boehringer Ingelheim and Eli
Latest news
-
Merck CFO: we’re not only about Keytruda
shrug off a 12% decline for diabetes treatment Januvia (sitagliptin) on pricing pressure.
-
Novo Nordisk gets FDA okay for new diabetes hope
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's DPP-4 inhibitor Januvia(sitagliptin), Boehringer Ingelheim and Eli Lilly's SGLT2
-
Novo uses voucher for speedy answer on oral semaglutide
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's Januvia (sitagliptin) Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) and
-
Analysts look beyond Keytruda in Merck’s future
Chief executive Ken Frazier took pains to point to other growth spots in MSD’s portfolio, particularly as diabetes blockbuster Januvia (sitagliptin) showed signs of weakness again after a return to
-
Reference price bill tabled in US House and Senate
savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens), Merck &Co’s Januvia (sitagliptin) for diabetes, and Astellas/Pfizer’s prostate cancer therapy Xtandi (enzalutamide).
More from news
Approximately 8 fully matching, plus 88 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
-
Interview: Christopher Boulton, AstraZeneca
sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- GSK discontinues two feladilimab trials in head and neck cancer
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Live Webinar: Advancing Human Health Through Precise Measures of Movement, Cognition & Biometrics
- Live Webinar: How to Simplify Genetics & Raise Awareness Around Orphan Diseases
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
